Mar 11, 2010 by Brian Orelli, PhDFDA Still Has a Bone to Pick With These DrugmakersOsteoporosis drugs remain under the microscope.
Mar 10, 2010 by Brian Orelli, PhDYou Paid How Much for That?Abbott steps up where Biogen Idec wouldn't.
Mar 10, 2010 by Brian Orelli, PhDOne Animal of an M&A DealMerck and Sanofi rekindle their animal love.
Mar 9, 2010 by Brian Orelli, PhDThe Opportunity That Wasn'tOpportunity? Good. Opportunistic infections? Bad.
Mar 9, 2010 by Brian Orelli, PhDAre Billions of Dollars in Revenue at Risk?Vaccine makers' lawsuit protection is called into question.
Mar 8, 2010 by Brian Orelli, PhDReally? A 59% Share Price Jump for That?Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
Mar 8, 2010 by Brian Orelli, PhDPfizer Still Dealing With Antitrust IssuesThe pharma giant sells off some more animal health assets.
Mar 5, 2010 by Brian Orelli, PhDHow to Replace $6.1 Billion in Lost RevenueIt's not easy, but Bristol-Myers will give it a shot.
Mar 4, 2010 by Brian Orelli, PhDBest in Class ... For NowSanofi's new prostate cancer drug is better than nothing.
Mar 3, 2010 by Brian Orelli, PhDJudge's Ruling Has Brand and Generic Drugmakers SmilingBoth of them are happy -- how can that be? This mystery involves the FDA, of course.
Mar 3, 2010 by Brian Orelli, PhDA Costly Missed ConnectionDimebon's phase 3 failure costs Medivation shareholders 67%.
Mar 2, 2010 by Brian Orelli, PhDMerck: Poised for Growth and Eager to GoMerck needs its new, stronger, post-acquisition pipeline to pay off.
Mar 1, 2010 by Brian Orelli, PhDThe Tapeworm in Buffett's SideRising health-care costs are killing the economy, says the Oracle of Omaha.
Feb 26, 2010 by Brian Orelli, PhDPolitical Theater: More Entertaining Than HelpfulHealth-care reform, like health-care stocks, remains still stuck in limbo.
Feb 26, 2010 by Brian Orelli, PhDBoning Up on Pfizer's DrugFablyn looks OK on paper, but that isn't going to cut it in the crowded osteoporosis market.
Feb 26, 2010 by Brian Orelli, PhDA Risky Deal, but at Least It's CheapGlaxo licenses a preclinical compound from Regulus.
Feb 26, 2010 by Brian Orelli, PhDDrug Company Cost Cuts: Careful What You Wish ForResearch and development is the lifeblood of future revenue.
Feb 25, 2010 by Brian Orelli, PhDWeekly Walk of Shame: Partisan Posturing on Health-Care ReformOur portfolios may not like it, but our pocketbooks need health-care reform.
